Monitoring and Safety Considerations for Upadacitinib in Alopecia Areata

Regulatory Context

The American Academy of Dermatology notes that Janus kinase (JAK) inhibitors, including upadacitinib, are approved or under investigation for multiple dermatologic and systemic conditions such as alopecia areata【1】.

The American Academy of Dermatology reports that the FDA has issued class‑wide warnings for JAK inhibitors, highlighting an increased risk of serious cardiovascular events, malignancy, thromboembolism, and mortality based on data from other JAK inhibitors in different patient populations【1】.

The American Academy of Dermatology recommends baseline and ongoing laboratory monitoring for patients receiving upadacitinib, including a complete blood count with differential at baseline and after treatment initiation【3】.
Baseline assessment of liver enzymes and periodic re‑evaluation during therapy are advised to detect potential hepatotoxicity【1】.
A lipid panel should be obtained 12 weeks after starting upadacitinib to monitor for dyslipidemia【3】.
Screening for viral hepatitis, tuberculosis, and pregnancy should be performed before treatment initiation to identify contraindications and guide safe use【2】.

The American Academy of Dermatology advises that live vaccines be avoided in patients treated with upadacitinib; such vaccines should be administered prior to therapy commencement【1】【3】.